All In Biotech

Drug Trial Radar · NCT07847905

A Phase I/II of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors

A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

90

Planned (sponsor's estimate)

Start

Oct 20, 2026

Primary completion

Oct 19, 2030

Study completion Aug 19, 2031

Sponsor

Lead sponsor
LaNova Medicines LimitedIndustry
Sponsor type
Industry
First posted
Sep 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in participants with advanced solid tumors. For Phase II, to assess the preliminary anti-tumor activity of IMP in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumor Cancer

Interventions

  • LM-364 for injectionDrug

    Q3W, Intravenous infusion

  • TislelizumabDrug

    Q3W, Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT)Time frame: 78 Weeks
  2. Adverse events (AEs)Time frame: 78 weeks
  3. serious adverse events (SAEs)Time frame: 78 weeks
  4. TemperaturesTime frame: 78 weeks
  5. Pulse in BPMTime frame: 78 weeks
  6. Blood Pressure in mmHgTime frame: 78 weeks
  7. Weight in KgTime frame: 78 weeks
  8. Height in centimeterTime frame: 78 weeks
  9. Laboratory examinations--Blood Routine examination-Complete Blood CountTime frame: 78 weeks
  10. Laboratory examinations--Blood biochemistry- Electrolytes and Metabolic ParametersTime frame: 78 weeks
  11. Laboratory examinations-Urine Routine test-UrinalysisTime frame: 78 weeks
  12. Laboratory examinations--Coagulation function-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT)Time frame: 78 weeks
  13. Laboratory examinations--Thyroid function-For the detection of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4)Time frame: 78 weeks
  14. Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentageTime frame: 78 weeks
  15. 12-lead electrocardiogram (ECG) in HRTime frame: 78 weeks
  16. 12-lead electrocardiogram (ECG) in RRTime frame: 78 weeks
  17. 12-lead electrocardiogram (ECG) in PRTime frame: 78 weeks
  18. 12-lead electrocardiogram (ECG) in QRSTime frame: 78 weeks
  19. 12-lead electrocardiogram (ECG) in QTTime frame: 78 weeks
  20. 12-lead electrocardiogram (ECG) in QTcFTime frame: 78 weeks
  21. ECOG score-Cooperative Oncology Group scoreTime frame: 78 weeks
  22. Objective Response Rate (ORR)Time frame: 52 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • the first affiliated hospital of Henan medical University

    Xinxiang, Henan, China

  • Taihe Hospital Affiliated Hospital of Hubei University of Medicine

    Shiyan, Hubei, China

  • Hunan cancer hospital

    Changsha, Hunan, China

  • Liaocheng People's Hospital

    Liaocheng, Shandong, China

  • FuDan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • The First School of Medicine, School of Information and Engineering,The First Affliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.